natgillin/translations-raw huggingface dataset:
What is Folotyn?
Kaj je zdravilo Folotyn?
Folotyn was expected to be used to treat adults with peripheral T-cell lymphoma, which is a cancer of a type of white blood cell called T-cells.
Zdravilo Folotyn naj bi se uporabljalo za zdravljenje odraslih bolnikov s perifernim T-celičnim limfomom, kar je rak vrste belih krvnih celic, imenovanih T-celice.
Therefore, at that point in time, the CHMP was of the opinion that the benefits of Folotyn did not outweigh its risks and recommended that it be refused marketing authorisation.
Posledično je CHMP tedaj menil, da koristi zdravila Folotyn ne odtehtajo z njim povezanih tveganj, zato je priporočil zavrnitev dovoljenja za promet z zdravilom.
The company informed the CHMP that there are no consequences on patients currently included in clinical trials or compassionate use programmes with Folotyn.
Družba je CHMP obvestila, da zavrnitev nima nobenih posledic za bolnike, ki trenutno sodelujejo v kliničnih preskušanjih ali programih sočutne uporabe zdravila Folotyn.
The company that applied for the authorisation is Allos Therapeutics Limited.
Vlogo za dovoljenje za promet z zdravilom je predložila družba Allos Therapeutics Limited.
On 19 January 2012, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Folotyn, intended for the treatment of peripheral T-cell lymphoma.
Odbor za zdravila za uporabo v humani medicini (CHMP) je 19. januarja 2012 sprejel negativno mnenje in priporočil zavrnitev vloge za dovoljenje za promet z zdravilom Folotyn, namenjenim zdravljenju perifernega T-celičnega limfoma.
What was Folotyn expected to be used for?
Za kaj naj bi se zdravilo Folotyn uporabljalo?
DHFR is necessary for the production of new DNA, which is required for cells to divide and multiply.
DHFR je potreben za nastajanje novih DNK, ki so potrebne
How is Folotyn expected to work?
Kako naj bi zdravilo Folotyn delovalo?
Folotyn was designated an ‘orphan medicine' (a medicine to be used in rare diseases) on 13 April 2007 for the treatment of peripheral T-cell lymphoma.
Zdravilo Folotyn je bilo 13. aprila 2007 določeno kot „zdravilo sirota” (zdravilo za zdravljenje redkih bolezni) za zdravljenje perifernega T-celičnega limfoma.
The CHMP was of the opinion that there was insufficient evidence to establish the benefits of Folotyn in the treatment of peripheral T-cell lymphoma.
CHMP je bil mnenja, da ni dovolj dokazov za potrditev koristi zdravila Folotyn pri zdravljenju perifernega T-celičnega limfoma.
In particular, the Committee considered that the data submitted by the applicant were insufficient to establish the benefits of Folotyn in the treatment of peripheral T-cell lymphoma.
Odbor je zlasti menil, da podatki, ki jih je predlagatelj predložil, ne zadoščajo za potrditev koristi zdravila Folotyn pri zdravljenju perifernega Tceličnega limfoma.
expected to block the enzyme's activity, inhibiting the division of the cancer cells and eventually killing them.
Po pričakovanjih naj bi z vezavo na DHFR pralatreksat preprečil dejavnost encima z zaviranjem delitve rakavih celic in njihovo posledično odmrtje.
This summary was last updated in 04-2009.
Ta povzetek je bil nazadnje posodobljen 04-2009.
Modigraf is taken twice a day, usually in the morning and evening.
Zdravilo Modigraf se jemlje dvakrat dnevno, ponavadi zjutraj in zvečer.
One study involved 28 children who were given the medicine for up to one year.
V eno študijo je bilo vključenih 28 otrok, ki so zdravilo prejemali do enega leta.
This means that it reduces the activity of the immune system (the body's natural defences).
To pomeni, da zmanjšuje aktivnost imunskega sistema (naravno obrambo telesa).
In the first study, 79% of patients given Modigraf (22 out of 28) did not have organ rejection.
V prvi študiji pri 79 % bolnikov, ki so prejemali zdravilo Modigraf (22 od 28), ni prišlo do zavrnitve organa.
Other information about Modigraf:
Druge informacije o zdravilu Modigraf:
Because tacrolimus has been in use for many years, the company presented results of studies from the scientific literature on the effectiveness of tacrolimus in organ transplantation.
Ker se takrolimus uporablja že več let, je družba predstavila izsledke študij iz znanstvene literature o učinkovitosti takrolimusa pri presaditvi organov.
In the second study, the difference between the total number of rejections for the two medicine combinations was not considered to be relevant.
V drugi študiji razlika med skupnim številom zavrnitev za kombinaciji obeh zdravil ni štela za pomembno.
Tacrolimus has been available in the European Union (EU) for preventing organ rejection since the mid-1990's.
Takrolimus je v Evropski uniji na voljo za preprečevanje zavrnitve organa od sredine devetdesetih let prejšnjega stoletja.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) MODIGRAF EPAR summary for the public
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) MODIGRAF Povzetek EPAR za javnost
Modigraf was not compared with any other medicine.
Zdravila Modigraf niso primerjali z nobenim drugim zdravilom.
The Committee recommended that Modigraf be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Modigraf odobri dovoljenje za promet.
The European Commission granted a marketing authorisation valid throughout the European Union for Modigraf to Astellas Pharma Europe B.V. on 15 May 2009.
Evropska komisija je dovoljenje za promet z zdravilom Modigraf, veljavno po vsej Evropski uniji, odobrila družbi Astellas Pharma Europe B.V.
Doses are calculated based on the patient's weight.
Odmerki se izračunajo na podlagi bolnikove telesne mase.
What benefit has Modigraf shown during the studies?
Kakšne koristi je zdravilo Modigraf izkazalo med študijami?
The second study involved 185 children who were given either Modigraf with corticosteroids (a group of immunosuppressant medicine) or a combination of other immunosuppressant medicines (cicosporin, azathioprine and corticosteroids) for one year.
V drugo študijo je bilo vključenih 185 otrok, ki so eno leto prejemali zdravilo Modigraf s kortikosteroidi (skupino imunosupresivnih zdravil) ali kombinacijo drugih imunosupresivnih zdravil (ciklosporin, azatioprin in kortikosteroidi).
Modigraf is for long-term use.
Zdravilo Modigraf je predvideno za dolgotrajno uporabo.
Modigraf can also be used to treat organ rejection when other immunosuppressive medicines are not effective.
Zdravilo Modigraf se lahko uporablja tudi za zdravljenje zavrnitve organa, ko druga imunosupresivna zdravila niso učinkovita.
The most common side effects with Modigraf (seen in more than 1 patient in 10) are diabetes, hyperglycaemia (high blood glucose), hyperkalaemia (high blood potassium), insomnia (difficulty sleeping), headache, tremor (shaking), hypertension (high blood pressure), diarrhoea, nausea (feeling sick), abnormal liver function test (abnormal level of liver enzymes), and kidney problems.
Najpogostejši neželeni učinki (opaženi pri več kot enem bolniku izmed 10) so sladkorna bolezen, hiperglikemija (povečane ravni glukoze v krvi), hiperkaliemija (povečane ravni kalija v krvi), nespečnost (motnje spanja), glavobol, tremor (tresavica), hipertenzija (visok krvni tlak), driska, navzeja (slabost), neobičajni rezultati jetrnih testov (neobičajne ravni jetrnih encimov) in težave z ledvicami.
Modigraft was studied in two main studies in children who had had a liver transplant.
Zdravilo Modigraft so proučevali v dveh glavnih študijah pri otrocih, pri katerih so opravili presaditev jeter.
It is available as sachets (0.2 mg and 1 mg) containing granules that are made up into an oral suspension.
Na voljo je v vrečkah (0,2 mg in 1 mg), ki vsebujejo zrnca za pripravo peroralne raztopine.
It also looked at the number of organ rejections in patients that did not respond to corticosteroids.
V tej študiji so ugotavljali tudi, koliko je bilo zavrnitev organov pri bolnikih, ki se niso odzvali na kortikosteroide.
The Committee for Medicinal Products for Human Use (CHMP) was of the opinion that in terms of effectiveness and safety, Modigraf was similar to other tacrolimus medicines available as capsules.
Odbor za zdravila za uporabo v humani medicini (CHMP) je menil, da je bilo zdravilo Modigraf glede učinkovitosti in varnosti podobno drugim zdravilom s takrolimusom, ki so na voljo v obliki kapsul.
Treatment with Modigraf should only be prescribed by doctors who have experience in the management of transplant patients.
Zdravljenje z zdravilom Modigraf sme predpisati samo zdravnik z izkušnjami z zdravljenjem bolnikov s presadki.
Tacrolimus acts on some special cells in the immune system called T-cells that are primarily responsible for attacking the transplanted organ (organ rejection).
Takrolimus učinkuje na nekatere posebne celice v imunskem sistemu, imenovane celice T, ki napadejo presajeni organ (zavrnitev organa).
Modigraf is used in adults and children who have had a kidney, liver or heart transplant, to prevent rejection (when the immune system attacks the transplanted organ).
Zdravilo Modigraf se uporablja pri odraslih in otrocih, pri katerih je bila opravljena presaditev ledvic, jeter ali srca, za preprečevanje zavrnitve presadka (ko imunski sistem napade presajeni organ).
Modigraf also offered the possibility of giving more exact doses and may be more easily administered to young children.
Pri zdravilu Modigraf je bila na voljo tudi možnost dajanja natančnejših odmerkov, zaradi česar ga je laže dajati majhnim otrokom.
Because Modigraf contains granules, it allows for making fine adjustments in dosing and provides an alternative for young children and others unable to swallow capsules.
Ker zdravilo Modigraf vsebuje zrnca, je njegovo odmerjanje lahko prilagodljivo, zato je alternativna možnost pri majhnih otrocih in drugih, ki ne morejo pogoltniti kapsul.
Modigraf should not be used in people who may be hypersensitive (allergic) to tacrolimus or any of the other ingredients or to other macrolides (medicines with a similar structure to tacrolimus).
Zdravila Modigraf ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) takrolimus ali katero koli drugo sestavino ali na druge makrolide (zdravila s podobno sestavo kot takrolimus).
The main measure of effectiveness was based on the number of patients who did not have organ rejection.
Glavno merilo učinkovitosti je temeljilo na številu bolnikov, pri katerih ni prišlo do zavrnitve organa.
In the prevention of rejection, the dose of Modigraf to use depends on the type of transplant the patient has received.
Odmerek zdravila Modigraf za preprečevanje zavrnitve je odvisen od vrste presadka, ki ga je bolnik prejel.
Modigraf is similar to another tacrolimus-containing medicine, Prograf or Prograft, which is available as capsules.
Zdravilo Modigraf je podobno drugemu zdravilu, ki vsebuje takrolimus, zdravilu Prograf ali Prograft, ki je na voljo v kapsulah.
What is the risk associated with Modigraf?
Kakšna tveganja so povezana z zdravilom Modigraf?
The main measure of effectiveness in this study was based on the number of patients who did not have organ rejection.
V tej študiji je glavno merilo učinkovitosti temeljilo na številu bolnikov, pri katerih ni prišlo do zavrnitve organa.
For the full list of all side effects reported with Modigraf, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Modigraf, glejte navodilo za uporabo.
Modigraf was effective at preventing organ rejection in children who had had a liver transplant.
Zdravilo Modigraf je bilo učinkovito pri preprečevanju zavrnitve organov pri otrocih, pri katerih je bila opravljena presaditev jeter.
Doctors should monitor the levels of tacrolimus in the blood to check that they stay within predefined ranges.
Da bi se zdravnik prepričal, da koncentracije takrolimusa v krvi ostajajo znotraj predhodno določenih razponov, jih mora spremljati.
Modigraf is a medicine that contains the active substance tacrolimus.
Modigraf je zdravilo, ki vsebuje zdravilno učinkovino takrolimus.
The full EPAR for Modigraf can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Modigraf je na voljo tukaj.
The CHMP decided that Modigraf's benefits are greater than its risks for prophylaxis of transplant rejection in kidney, liver and heart recipients, and in the treatment of rejection resistant to treatment with other immunosuppressive medicinal products.
Odbor za zdravila za uporabo v humani medicini je zaključil, da so koristi zdravila Modigraf za preprečevanje zavrnitve presadkov ledvic, jeter in srca ter pri zdravljenju zavrnitve, ki je ni mogoče zdraviti z drugimi imunosupresivnimi zdravili, večje od z njim povezanih tveganj.
When treating rejection, the same doses may be used in kidney and liver transplants.
Enaki odmerki se lahko uporabljajo za zdravljenje zavrnitve pri presadkih ledvic in jeter.
However, the Modigraf combination was more effective than the other combination at preventing organ rejections that could not be treated by corticosteroids.
Vendar pa je bilo zdravilo Modigraf v kombinaciji z drugimi zdravili pri preprečevanju zavrnitve organov, ki je ni bilo mogoče zdraviti s kortikosteroidi, bolj učinkovito kot druga kombinacija.
Why has Modigraf been approved?
Zakaj je bilo zdravilo Modigraf odobreno?
What is Modigraf used for?
Za kaj se zdravilo Modigraf uporablja?
What is Modigraf?
Kaj je zdravilo Modigraf?
How has Modigraf been studied?
Kako je bilo zdravilo Modigraf raziskano?
How is Modigraf used?
Kako se zdravilo Modigraf uporablja?
How does Modigraf work?
Kako zdravilo Modigraf deluje?
For heart transplants the dose is 0.15 mg/kg/day for adults and 0.2 to 0.3 mg/kg for children.
Odmerki po presaditvi srca znašajo 0,15 mg/kg/dan pri odraslih in od 0,2 do 0,3 mg/kg pri otrocih.
Tacrolimus, the active substance in Modigraf, is an immunosuppressive agent.
Zdravilna učinkovina zdravila Modigraf je takrolimus, ki je sredstvo za zaviranje imunske odzivnosti.
The starting daily dose for heart transplant patients is 0.075 mg/kg for adults and 0.3 mg/kg for children.
Pri bolnikih, pri katerih je bila opravljena presaditev srca, znaša začetni dnevni odmerek 0,075 mg/kg pri odraslih in 0,3 mg/kg pri otrocih.
In kidney transplant patients, the starting daily dose is 0.2 to 0.3 mg per kilogram body weight for adults and 0.3 mg/kg for children.
Pri bolnikih, pri katerih je bila opravljena presaditev ledvic, znaša začetni dnevni odmerek 0,2 do 0,3 mg na kilogram telesne mase pri odraslih in 0,3 mg/kg pri otrocih.
In liver transplant patients, the starting daily dose is 0.1 to 0.2 mg/kg for adults and 0.3 mg/kg for children.
Pri bolnikih, pri katerih je bila opravljena presaditev jeter, znaša začetni dnevni odmerek 0,1 do 0,2 mg/kg na kilogram telesne mase pri odraslih in 0,3 mg/kg pri otrocih.
With some drinks, the mixture may change colour and possibly become cloudy.
Pri nekaterih pijačah lahko mešanica spremeni barvo in morda postane motna.
3 years.
65 let.
Tell your doctor if you are taking, have recently taken or might take any other medicines
Obvestite svojega zdravnika, če jemljete ali ste pred kratkim jemali ali pa boste morda začeli jemati katerokoli drugo zdravilo.
• Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached
• ob vsakršni spremembi sistema za obvladovanje tveganj, zlasti kadar je tovrstna sprememba posledica prejema novih informacij, ki lahko privedejo do znatne spremembe razmerja med koristmi in tveganji ali kadar je ta sprememba posledica tega, da je bil dosežen pomemben mejnik (farmakovigilančni ali povezan z zmanjševanjem tveganja),
Your doctor will tell you how many ZYPREXA VELOTAB tablets to take and how long you should continue to take them.
Zdravnik vam bo povedal, koliko ZYPREXA VELOTAB tablet morate vzeti in kako dolgo naj bi jih jemali.
• If you have been previously diagnosed with eye problems such as certain kinds of glaucoma (increased pressure in the eye).
- če so vam v preteklosti ugotovili težave z očmi kot je določena vrsta glavkoma (povišan tlak v očesu).
Date of latest renewal: 12 September 2006
Datum pridobitve dovoljenja za promet: 3. februar 2000 Datum zadnjega podaljšanja dovoljenja za promet: 12. september 2006
ZYPREXA VELOTAB belongs to a group of medicines called antipsychotics and is used to treat the following conditions:
Zdravilo ZYPREXA VELOTAB spada v skupino zdravil, imenovanih antipsihotiki, in se uporablja za zdravljenje naslednjih bolezni:
In cases where dose increments of 2.5 mg are considered necessary, ZYPREXA coated tablets should be used.
V primerih, kjer so nujna višanja odmerkov po 2,5 mg, je treba uporabljati ZYPREXA obložene tablete.
These preservatives are known to cause urticaria.
Za ta dva konzervansa je znano, da povzročata koprivnico.
Generally, delayed type reactions such as contact dermatitis may occur, but rarely immediate reactions with bronchospasm may occur.
Na splošno lahko pride do reakcij pozne preobčutljivosti, kot je kontaktni dermatitis, le redko pa se pojavijo reakcije takojšnje preobčutljivosti z bronhospazmom.
• The use of ZYPREXA VELOTAB in elderly patients with dementia is not recommended as it may have serious side effects.
• Uporaba zdravila ZYPREXA VELOTAB ni priporočljiva pri starejših bolnikih z demenco, saj lahko povzroči resne neželene učinke.
Since the orodispersible tablet is fragile, it should be taken immediately on opening the blister.
Ker je orodisperzibilna tableta krhka, jo je treba zaužiti takoj po odprtju razdelka pretisnega omota.
In 44 patients with schizophrenia > 65 years of age, dosing from 5 to 20 mg/day was not associated with any distinguishing profile of adverse events.
44 bolnikih s shizofrenijo, starejših od 65 let, odmerjanje od 5 do 20 mg/dan ni bilo povezano s kakim razločevalnim profilom neželenih učinkov.
This may occur immediately or some time after you take ZYPREXA VELOTAB.
Do tega lahko pride bodisi takoj bodisi nekaj časa po tem, ko ste zaužili zdravilo ZYPREXA VELOTAB.
In clinical studies, the average olanzapine exposure was approximately 27% higher in adolescents.
V kliničnih študijah je bila povprečna izpostavitev približno 27 % višja pri mladostnikih.
You can also place the tablet in a full glass or cup of water, orange juice, apple juice, milk or coffee, and stir.
Tableto lahko daste tudi v poln kozarec ali skodelico vode, pomarančnega soka, jabolčnega soka, mleka ali kave in tekočino premešate.
• Tell the doctor if you or someone else in your family has a history of blood clots, as medicines like these have been associated with the formation of blood clots.
• Če ste vi ali kdo iz vaše družine v preteklosti imeli krvne strdke, morate o tem obvestiti svojega zdravnika, saj lahko zdravila, kot je to, povzročijo nastanek krvnih strdkov.
Orodispersible tablet is the technical name for a tablet which dissolves directly in your mouth, so that it can be easily swallowed.
Orodisperzibilna tableta je strokovno ime za tableto, ki se raztopi neposredno v ustih, tako da jo zlahka pogoltnete.
If this happens after you have been given ZYPREXA VELOTAB tell your doctor.
Če se vam to zgodi po tem, ko ste prejeli zdravilo ZYPREXA VELOTAB, povejte svojemu zdravniku.
However, olanzapine (5-20 mg) demonstrated a comparable safety profile in female (n=467) as in male patients (n=869).
20 mg) pokazal primerljiv profil varnosti tako pri bolnikih ženskega (n = 467) kot moškega spola (n = 869).
Gently push the tablet out.
Rahlo potisnite tableto ven.
The following table summarises the adverse reactions reported with a greater frequency in adolescent patients (aged 13-17 years) than in adult patients or adverse reactions only identified during short term clinical trials in adolescent patients.
Naslednja tabela vključuje neželene učinke, ki so jih poročali z višjo pogostnostjo pri mladostnikih (starih 13-17 let) kot pri odraslih bolnikih ali neželene učinke, ki so jih ugotovili samo v kratkoročnih kliničnih preskušanjih pri mladostnikih.
Clinically significant weight gain (≥ 7%) appears to occur more frequently in the adolescent population compared to adults with comparable exposures.
(≥ 7 %) pojavlja pogosteje pri populaciji mladostnikov v primerjavi z odraslimi pri primerljivi izpostavljenosti.
Carefully peel off the backing.
Previdno odstranite hrbtni del.
Do not handle the tablets with wet hands as the tablets may break up.
Ne dotikajte se jih z mokrimi rokami, ker se lahko zdrobijo.
• carbamazepine (an anti-epileptic and mood stabiliser), fluvoxamine (an antidepressant) or ciprofloxacin (an antibiotic) - it may be necessary to change your ZYPREXA VELOTAB dose.
• karbamazepin (antiepileptik in stabilizator razpoloženja), fluvoksamin (antidepresiv) ali ciprofloksacin (antibiotik) - morda bo treba spremeniti vaš odmerek zdravila ZYPREXA VELOTAB.
In patients with Parkinson's disease ZYPREXA VELOTAB may worsen the symptoms.
Pri bolnikih s Parkinsonovo boleznijo lahko zdravilo ZYPREXA VELOTAB poslabša simptome.
ZYPREXA VELOTAB is available in packs containing 28, 35, 56, 70 or 98 tablets.
Zdravilo ZYPREXA VELOTAB je na voljo v pakiranjih po 28, 35, 56, 70 ali 98 tablet.
As a routine precaution, if you are over 65 years your blood pressure may be monitored by your doctor.
Kot običajen previdnostni ukrep vam lahko vaš zdravnik nadzoruje krvni tlak, če ste stari več kot
Such factors possibly contribute to the higher average exposure observed in adolescents.
Možno je, da taki dejavniki vplivajo na višjo povprečno izpostavitev,
This leaflet was last revised in {month XXXX} Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu
Navodilo je bilo nazadnje revidirano {mesec LLLL} Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu.
(including pulmonary embolism and deep vein thrombosis) (see section 4.4)
(vključno s pljučno embolijo in globoko vensko trombozo) (glejte poglavje
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to medical prescription.
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE Predpisovanje in zdravila je le na recept.
Alternatively, it may be dispersed in a full glass of water or other suitable beverage (orange juice, apple juice, milk or coffee) immediately before administration.
Drug način uporabe je, da tableto dispergiramo v polnem kozarcu vode ali druge ustrezne pijače (pomarančni sok, jabolčni sok, mleko ali kava) neposredno pred zaužitjem.
Your doctor should do blood tests to check blood sugar and certain fat levels before you start taking ZYPREXA VELOTAB and regularly during treatment.
Vaš zdravnik mora opraviti krvni test za preiskavo sladkorja v krvi in nivo določenih maščob pred začetkom jemanja zdravila ZYPREXA
Removal of the intact orodispersible tablet from the mouth is difficult.
Nedotaknjeno orodisperzibilno tableto je iz ust težko odstraniti.
The mean increase in olanzapine Cmax following fluvoxamine was 54 % in female nonsmokers and 77 % in male smokers.
Srednje zvišanje Cmax olanzapina po dajanju fluvoksamina je bilo 54 % pri ženskah nekadilkah in
Children and adolescents ZYPREXA VELOTAB is not for patients who are under 18 years.
Zdravilo ZYPREXA VELOTAB ni namenjeno bolnikom, mlajšim od 18 let.
Olanzapine orodispersible tablet is bioequivalent to olanzapine coated tablets, with a similar rate and extent of absorption.
Olanzapin orodisperzibilna tableta je bioekvivalentna olanzapin obloženim tabletam, s podobno hitrostjo in obsegom absorpcije.
It has the same dosage and frequency of administration as olanzapine coated tablets.
Ima enako odmerjanje in pogostnost jemanja kot olanzapin obložene tablete.
It is important that you carry on taking ZYPREXA VELOTAB for as long as your doctor tells you.
Pomembno je, da nadaljujete z jemanjem zdravila ZYPREXA VELOTAB tako dolgo, kot vam naroči zdravnik.
The major circulating metabolite is the 10-N-glucuronide, which does not pass the blood brain barrier.
V krvi je poglavitni metabolit 10N-glukuronid, ki ne prehaja skozi krvno-možgansko pregrado.